A review of 1246 articles indicates that C-reactive protein acts as a risk enhancer for cardiovascular disease, aiding in risk stratification and predicting the prognosis of recurrent events.
Cardiovascular disease (CVD) is the most common cause of death worldwide, with coronary atherosclerotic heart disease (CHD) accounting for the majority of events. Evidence demonstrates that inflammation plays a vital role in the development of CHD. The association between C-reactive protein (CRP), a representative inflammatory biomarker, and atherosclerosis (AS), CHD, and inflammation has attracted attention. Therefore, we conducted an extensive search on PubMed using the aforementioned terms as search criteria and identified a total of 1246 articles published from January 2000 to April 2024. Both review and research-based articles consistently indicate CRP as a risk enhancer for CVD, contributing to the refinement of risk stratification and early identification of apparently healthy at-risk populations. Additionally, CRP reflects disease progression and predicts the prognosis of recurrent cardiovascular events. Anti-inflammatory therapeutic strategies targeting CRP also provide new treatment options for patients. This review focuses on the link between CRP and CHD, highlighting how CRP is involved in the pathological progression of AS and its potential value for clinical applications.
Zhao et al. (Sat,) conducted a review in Coronary atherosclerotic heart disease. C-reactive protein (CRP) assessment was evaluated. A review of 1246 articles indicates that C-reactive protein acts as a risk enhancer for cardiovascular disease, aiding in risk stratification and predicting the prognosis of recurrent events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: